$11.73
0.423.71%
Last update: Nov 10, 5:23 AM
Cullinan Therapeutics Inc
CGEMNASDAQ
Cullinan Therapeutics rose 57.7% from $7.44 to $11.73, ahead of the S&P 500's +10.5%. Its worst day was Sep 23 (−22.2%), and its low came Nov 10 at $7.44.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Cullinan Therapeutics shares rose 36.5%, while the S&P 500 rose 1.5%.
+36.5%, the year's best day, on 5M shares, the year's heaviest volume · S&P 500 +1.5%
Story events cover the past 12 months · Times ET
CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML31% CR/CRh rate
+17.5% · S&P 500 −0.3%
EPS of $-0.77 beat the $-0.82 estimate on $0.00 revenue (est. $9.9M).
−2.6% · S&P 500 −0.2%
EPS of $-0.75 beat the $-0.84 estimate on $0.00 revenue (est. $3.5M).
−1.8% · S&P 500 −0.3%
Cullinan Therapeutics shares rose 15.1%, while the S&P 500 fell 0.3%.
+15.1% · S&P 500 −0.3%
EPS of $-0.81 beat the $-0.82 estimate on $0.00 revenue (est. $7.0M).
+1.9% · S&P 500 −0.2%
Cullinan Therapeutics closed at its highest level of the year, 208.5% above where the year started.
+5.2% · S&P 500 +0.3%
Cullinan Therapeutics shares fell 22.2%, while the S&P 500 fell 0.7%.
−22.2%, the year's worst day · S&P 500 −0.7%
Cullinan Therapeutics shares fell 20.7%, while the S&P 500 rose 1.7%.
−20.7% · S&P 500 +1.7%
Where it ended: a close of $11.73 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.83, revenue est. $402,000.00).
Nothing in the past 12 months.
All CGEM dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CGEM and SPY from Benzinga historical bars. Not investment advice.
